Chronic Hepatitis C Virus (HCV) Infection
Conditions
Brief summary
The primary efficacy endpoint is SVR12. The proportion of subjects achieving SVR12 with two-sided 95% CIs using the Wilson score method will be presented. Reasons for failure to achieve SVR12 will be summarized.
Detailed description
The proportion of subjects in the PP population experiencing virological failure (either on-treatment or post-treatment relapse by 12 weeks post treatment) will be estimated and presented with 95% CIs., The proportion of subjects in the PP population achieving SVR24 will be analyzed using the same method as SVR12.
Interventions
Sponsors
Atea Pharmaceuticals Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy endpoint is SVR12. The proportion of subjects achieving SVR12 with two-sided 95% CIs using the Wilson score method will be presented. Reasons for failure to achieve SVR12 will be summarized. | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of subjects in the PP population experiencing virological failure (either on-treatment or post-treatment relapse by 12 weeks post treatment) will be estimated and presented with 95% CIs., The proportion of subjects in the PP population achieving SVR24 will be analyzed using the same method as SVR12. | — |
Countries
Germany, Romania, Spain
Outcome results
None listed